ReviewJournal of the Canadian Association of Gastroenterology2024
Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease.
Review in Journal of the Canadian Association of Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Comparative Efficacy of Different Targeted Therapies in Patients With Moderate-to-Severe Ulcerative Colitis: Systematic Review/Network Meta-Analysis and Mechanistic Overview.Pharmacology research & perspectives · 2025Pooled it
- Article
- The Burden of Viral Respiratory Infections in Immunosuppressed Inflammatory Bowel Disease Patients.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Dual-targeted therapy with risankizumab and upadacitinib in medically complex Crohn's disease.Crohn's & colitis 360 · 2026Article
- Are All Cells Created Equal? Novel Cell-Based Regenerative Therapies in Inflammatory Bowel Disease.International journal of molecular sciences · 2026Review
- Efficacy and safety in the short-to-intermediate term of advanced combination therapy with upadacitinib for refractory Crohn's disease: real-world evidence from eastern China.Frontiers in medicine · 2026Article
- Future of inflammatory bowel disease treatment: A review of novel treatments beyond guidelines.World journal of methodology · 2025Review
- Lipidated IL-22 Alone or Combined with Immunomodulatory Agents Improves Disease Endpoints and Promotes Mucosal Healing in a Mouse Model of Chronic Dextran Sodium Sulfate-Induced Colitis.Digestive diseases and sciences · 2025Article
- Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions.Journal of clinical medicine · 2025Article
- Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores.Frontiers in pharmacology · 2025Article
- Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China.Therapeutic advances in gastroenterology · 2025Article
- Exploring Dual-Targeted Therapy in the Management of Moderate to Severe Inflammatory Bowel Disease: A Retrospective Study.Crohn's & colitis 360 · 2025Article
- Machine Learning of Serum Cytokine and Chemokine Profiles Can Classify Inflammatory Bowel Disease Beyond Clinical Diagnosis.Gastro hep advances · 2025Article
- Histopathological outcome predictors of quiescence/remission in inflammatory bowel diseases: A need being addressed.United European gastroenterology journal · 2024Article
- Real-World Outcomes of Dual Advanced Therapy in Children and Young Adults with Inflammatory Bowel Disease.Digestive diseases and sciences · 2024Article
- Cytokine Profile in Predicting the Effectiveness of Advanced Therapy for Ulcerative Colitis: A Narrative Review.Biomedicines · 2024Review
- Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey.Journal of clinical medicine · 2024Article
- Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease.International journal of molecular sciences · 2024Review
- Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologicals and small molecules have revolutionized the medical management of inflammatory bowel diseases (IBD), yet they are only effective in a proportion of patients, and their impact on changing the natural history of the disease is still debatable. Recently, the concept of combining targeted biologics and small-molecule therapies has been introduced to the treatment of IBD. Dual-targeted therapy (sequential and combined), which is the combination of two targeted therapies, might be a reasonable choice for patients to break through the therapeutic ceiling. A recent randomized clinical trial (VEGA) provided the first controlled evidence that the short-term combination of two biological agents may lead to superior disease control than either of the agents alone in patients with ulcerative colitis (UC) without jeopardizing safety. Multiple studies are underway in both Crohn's disease and UC. Additionally, real-world evidence is accumulating in IBD patients receiving combination therapies with concomitant IBD and extraintestinal manifestations or in patients with medically refractory IBD. Of note, the majority of these patients were exposed to multiple biological agents earlier and lost response to at least one of the agents in the combination. This review summarizes current knowledge regarding this attractive novel therapeutic option in IBD. Clearly, more controlled data are needed to evaluate optimal timing, efficacy, and mitigation of safety concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.